Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expressionRobert L. Ferris, Maura L. Gillison, George R. Blumenschein et al.|Oral Oncology|2018Cited by 802
Estimating and explaining the effect of education and income on head and neck cancer risk: INHANCE consortium pooled analysis of 31 case‐control studies from 27 countriesDavid I. Conway, Lorenzo Richiardi, Xavier Castellsagué et al.|International Journal of Cancer|2014Cited by 165
Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trialRobert I. Haddad, Robert L. Ferris, Fernando Concha‐Benavente et al.|Cancer|2019Cited by 98
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141Maura L. Gillison, Robert L. Ferris, George R. Blumenschein et al.|The Oncologist|2022Cited by 52